Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199809 · ClinicalTrials.gov registry record · Phase 1
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01199809 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 19 participants.
The verdict
NCT01199809, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This randomized, double-blind. placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with psoriatic arthritis who have or have had an inadequate response to oral disease-modifying antirheumatic drugs (DMARDs) or non-steroidal anti-rheumatic drugs (NSAIDs). Patients will be randomized in cohorts to receive either 6 intravenous doses of RO5310074 or placebo. Anticipated time on study treatment is 12 weeks.
Interventions
- DRUG Placebo
- DRUG RO5310074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199809
The ClinicalTrials.gov registry entry for NCT01199809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01199809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01199809 about?
NCT01199809 is a clinical study titled "A Study of RO5310074 in Patients With Psoriatic Arthritis". This randomized, double-blind. placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO5310074 in patients with psoriatic arthritis who have or have had an inadequate response to oral disease-modifying antirheumatic drugs (DMARDs) o...
What is the current status of trial NCT01199809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2011-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01199809?
The interventions under investigation include: Placebo (DRUG), RO5310074 (DRUG).
Who is sponsoring clinical trial NCT01199809?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.